|
Title
|
|
|
|
Targeted therapies for squamous cell carcinoma of the head and neck : current knowledge and future directions
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Despite progress in the therapeutic management of patients with squamous cell carcinoma of the head and neck (SCCHN), the mortality rate of patients presenting with advanced disease remains high. One approach to improve treatment efficacy is to add novel molecular targeted agents to the classical treatment regimens. Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have shown clinical benefits in palliative and curative settings. However, only a minority of patients presenting with recurrent or metastatic (RIM) SCCHN have meaningful tumor regression with these agents and virtually all who do develop acquired tumor resistance after a few months of treatment. For these reasons, other inhibitors of EGFR or molecules that interfere with known molecular pathways activated in SCCHN are of considerable interest, either as single agents or in combination with other treatment modalities. In this review, we discuss the different molecular therapeutic approaches explored in SCCHN. We also briefly outline new trial designs that could be used to accelerate the investigation of emerging therapeutic agents in this disease. (C) 2013 Elsevier Ltd. All rights reserved. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Cancer treatment reviews. - London
|
|
|
Publication
|
|
|
|
London
:
2014
|
|
|
ISSN
|
|
|
|
0305-7372
|
|
|
DOI
|
|
|
|
10.1016/J.CTRV.2013.09.007
|
|
|
Volume/pages
|
|
|
|
40
:3
(2014)
, p. 390-404
|
|
|
ISI
|
|
|
|
000331687800006
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|